Seonix Bio Launches SightScore Saliva Test for Glaucoma Risk in US

Seonix Bio announced Feb. 20 the US launch of SightScore, the first commercially available clinical polygenic risk score testing service for primary open-angle glaucoma.

Seonix, an Australian company with US offices in San Diego, California, said SightScore uses a saliva test to identify individuals at high risk for glaucoma, enabling earlier diagnosis and intervention and more personalized treatment.

The test is already available in Australia and New Zealand.

Seonix said SightScore looks at millions of genetic variants in a patient’s genome to create a personalized risk score for glaucoma. If a patient is already known to have glaucoma, it assesses the risk of progression. Clinicians receive patient reports through an online portal about four to six weeks after screening, Seonix’ website says.

The test is not suitable for assessing angle-closure glaucoma or juvenile glaucoma risk, Seonix said.